Cho BC et al. Amivantamab plus lazertinib vs osimertinib as first-line treatment in EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial. ESMO 2023;Abstract LBA14.

Passaro A et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study. Ann Oncol 2024;35(1):77-90. Abstract

Planchard D et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 2023;389(21):1935-48. Abstract

Tsuboi M et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med 2023;389(2):137-47. Abstract

Zhou C et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertion. N Engl J Med 2023;389(22):2039-51. Abstract